Swedish Orphan Biovitrum, also known as Sobi, will pay $27.50 a share in cash for Dova, plus a further $1.50 a share upon regulatory approval of Dova drug Doptelet for the treatment of chemotherapy-induced thrombocytopenia.
The total value of the deal is worth about $915 million.
The upfront consideration of $27.50 a share represents a premium of 36% to Dova's closing price on Friday, and a premium of 59% to the 30-day volume weighted average price.
Dova closed Friday at $20.19 and was more than 38% to $27.98 in trading on Monday.
The transaction is expected to close in the fourth quarter.
Save 57% During Our Fall Sale. Join Jim Cramer's Action Alerts PLUS investment club to become a smarter investor. Click here to sign up and save!